CellAction (Cell therapy Acceleration and Innovation), the cell and gene therapy laboratory at Institut Curie.
Accelerate cell and gene therapy development through collaborative programs, integrated process development and CMC process, reduced transfer timelines, and GMP-ready manufacturing solutions.
Offer overview
What this offer helps you achieve
Accelerate cell and gene therapy development through collaborative programs, integrated process development and CMC process, reduced transfer timelines, and GMP-ready manufacturing solutions.
Scientific and technical scope
Capabilities mobilised
Application fields
Use case: The EpCART Program
The EpCART program is a flagship example of CellAction’s capabilities in translating cutting-edge science into clinical innovation.
Expected to enter an early-phase clinical trial in 2026, EpCART builds on pioneering research led by Dr. Sebastian Amigorena and the Institut Curie teams. The program harnesses epigenetic reprogramming to enhance CAR-T cell potency, persistence, and long-term anti-tumor efficacy against difficult-to-treat cancers.
Within the project, CellAction plays a pivotal role in process development, optimizing the manufacturing workflow for the CAR-T product and ensuring its successful technology transfer to MEARY, the bioproduction facility in this project.
Impact: Accelerating the translation of breakthrough discoveries into next-generation cancer therapies and bringing transformative treatments to patients faster.
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Find an offer